dosed

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…

2 weeks ago

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform February 03, 2026 13:08 ET  | Source:…

3 weeks ago

RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy

February 03, 2026 13:06 ET  | Source: Restem Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L…

3 weeks ago

Biosplice Therapeutics Announces First Patient Dosed in InvestigatorInitiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD PlatinumResistant Ovarian Cancer

SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company advancing small-molecule inhibition of…

2 months ago

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma

Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs…

6 months ago

FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis…

6 months ago